RÉSUMÉ
Pancreatic duct epithelial cells have been suggested as a source of progenitors for pancreatic growth and regeneration. However, genetic lineage-tracing experiments with pancreatic duct-specific Cre expression have given conflicting results. Using immunofluorescence and flow cytometry, we show heterogeneous expression of both HNF1ß and SOX9 in adult human and murine ductal epithelium. Their expression was dynamic and diminished significantly after induced replication. Purified pancreatic duct cells formed organoid structures in 3D culture, and heterogeneity of expression of Hnf1ß and Sox9 was maintained even after passaging. Using antibodies against a second cell surface molecule CD51 (human) or CD24 (mouse), we could isolate living subpopulations of duct cells enriched for high or low expression of HNF1ß and SOX9. Only the CD24high (Hnfßhigh/Sox9high) subpopulation was able to form organoids.
Sujet(s)
Facteur nucléaire hépatocytaire HNF-1 bêta/métabolisme , Conduits pancréatiques/métabolisme , Facteur de transcription SOX-9/métabolisme , Adulte , Sujet âgé , Animaux , Antigènes CD24/métabolisme , Cellules épithéliales/métabolisme , Humains , Intégrine alphaV/métabolisme , Mâle , Souris , Souris de lignée C57BL , Adulte d'âge moyen , Organoïdes/métabolismeRÉSUMÉ
Diabetes, particularly type 1 diabetes, results from the lack of pancreatic ß-cells. ß-cell replenishment can functionally reverse diabetes, but two critical challenges face the field: 1. protection of the new ß-cells from autoimmunity and allorejection, and 2. development of ß-cells that are readily available and reliably functional. This chapter will examine the potential of endogenous replenishment of pancreatic ß-cells as a possible therapeutic tool if autoimmunity could be blunted. Two pathways for endogenous replenishment exist in the pancreas: replication and neogenesis, defined as the formation of new islet cells from pancreatic progenitor/stem cells. These pathways of ß-cell expansion are not mutually exclusive and both occur in embryonic development, in postnatal growth, and in response to some injuries. Since the ß-cell population is dramatically reduced in the pancreas of type 1 diabetes patients, with only a small fraction of the ß-cells surviving years after onset, replication of preexisting ß-cells would not be a reasonable start for replenishment. However, induction of neogenesis could provide a starting population that could be further expanded by replication. It is widely accepted that neogenesis occurs in the initial embryonic formation of the endocrine pancreas, but its occurrence anytime after birth has become controversial because of discordant data from lineage tracing experiments. However, the concept was built upon many observations from different models and species over many years. Herein, we discuss the role of neogenesis in normal growth and regeneration, as learned from rodent models, followed by an analysis of what has been found in humans.
Sujet(s)
Prolifération cellulaire , Diabète de type 1/physiopathologie , Cellules à insuline/cytologie , Ilots pancréatiques/cytologie , Animaux , Différenciation cellulaire , HumainsRÉSUMÉ
OBJECTIVE: In vitro expansion of beta-cells from adult human islets could solve the tissue shortage for cell replacement therapy of diabetes. Culture of human islet cells typically results in <16 cell doublings and loss of insulin expression. Using cell lineage tracing, we demonstrated that the expanded cell population included cells derived from beta-cells. Understanding the molecular mechanisms involved in beta-cell fate in vitro is crucial for optimizing expansion and redifferentiation of these cells. In the developing pancreas, important cell-fate decisions are regulated by NOTCH receptors, which signal through the hairy and enhancer of split (HES)-1 transcriptional regulator. Here, we investigated the role of the NOTCH signaling pathway in beta-cell dedifferentiation and proliferation in vitro. RESEARCH DESIGN AND METHODS: Isolated human islets were dissociated into single cells. beta-Cells were genetically labeled using a Cre-lox system delivered by lentiviruses. Cells were analyzed for changes in expression of components of the NOTCH pathway during the initial weeks in culture. HES-1 expression was inhibited by a small hairpin RNA (shRNA), and the effects on beta-cell phenotype were analyzed. RESULTS: Human beta-cell dedifferentiation and entrance into the cell cycle in vitro correlated with activation of the NOTCH pathway and downregulation of the cell cycle inhibitor p57. Inhibition of HES-1 expression using shRNA resulted in significantly reduced beta-cell replication and dedifferentiation. CONCLUSIONS: These findings demonstrate that the NOTCH pathway is involved in determining beta-cell fate in vitro and suggest possible molecular targets for induction of beta-cell redifferentiation following in vitro expansion.
Sujet(s)
Facteurs de transcription à motif basique hélice-boucle-hélice/génétique , Facteurs de transcription à motif basique hélice-boucle-hélice/métabolisme , Protéines à homéodomaine/génétique , Protéines à homéodomaine/métabolisme , Cellules à insuline/cytologie , Cellules à insuline/physiologie , Transduction du signal/physiologie , Adulte , Techniques de culture cellulaire , Différenciation cellulaire/physiologie , Division cellulaire/physiologie , Lignage cellulaire/physiologie , Cellules cultivées , Inhibiteur p27 de kinase cycline-dépendante/métabolisme , Humains , Petit ARN interférent , Récepteurs Notch/métabolisme , Facteur de transcription HES-1 , Régulation positive/physiologieRÉSUMÉ
Understanding and manipulating pancreatic beta-cell proliferation is a major challenge for pancreas biology and diabetes therapy. Recent studies have raised the possibility that human beta-cells can undergo dedifferentiation and give rise to highly proliferative mesenchymal cells, which retain the potential to redifferentiate into beta-cells. To directly test whether cultured beta-cells dedifferentiate, we applied genetic lineage tracing in mice. Differentiated beta-cells were heritably labeled using the Cre-lox system, and their fate in culture was followed. We provide evidence that mouse beta-cells can undergo dedifferentiation in vitro into an insulin-, pdx1-, and glut2-negative state. However, dedifferentiated beta-cells only rarely proliferate under standard culture conditions and are eventually eliminated from cultures. Thus, the predominant mesenchymal cells seen in cultures of mouse islets are not of a beta-cell origin.
Sujet(s)
Différenciation cellulaire/physiologie , Division cellulaire/physiologie , Cellules à insuline/cytologie , Animaux , Techniques de culture cellulaire , Amorces ADN , Gènes rapporteurs , Protéines à fluorescence verte/analyse , Protéines à fluorescence verte/génétique , Insuline/métabolisme , Sécrétion d'insuline , Cellules à insuline/physiologie , Souris , Souris transgéniques , Réaction de polymérisation en chaîneRÉSUMÉ
Beta-cell replacement represents the ultimate cure for type 1 diabetes, however it is limited by availability of organ donors. Adult human islets are difficult to propagate in culture, and efforts to expand them result in dedifferentiation. Here we describe conditions for expansion of adult human islet cells, as well as a way for their redifferentiation. Most cells in islets isolated from human pancreata were induced to replicate within the first week of culture in expansion medium. Cells were propagated for 16 population doublings, without a change in replication rate or noticeable cell mortality, representing an expansion of over 65,000-fold. Replication was accompanied by a decrease in expression of key beta-cell genes. Shift of the cells to differentiation medium containing betacellulin resulted in redifferentiation, as manifested by restoration of beta-cell gene expression and insulin content. These methods may allow transplantation of functional islet cells from single donors into multiple recipients.